Design and characterization of a new hybrid peptide from LL-37 and BMAP-27

References

• Gottlieb T, Nimmo GR. Antibiotic resistance is an emerging threat to public health: an urgent call to action at the antimicrobial resistance summit 2011. Med J Aust. 2011;194(6):281–283.21426279
   PubMedGoogle Scholar
• Spellberg B. The future of antibiotics. Crit Care Lond Engl. 2014;18(3):228. doi:10.1186/cc13948
   PubMed Web of Science ®Google Scholar
• Spellberg B, Bartlett J, Wunderink R, Gilbert DN. Novel approaches are needed to develop tomorrow’s antibacterial therapies. Am J Respir Crit Care Med. 2015;191(2):135–140. doi:10.1164/rccm.201410-1894OE25590154
   PubMed Web of Science ®Google Scholar
• Tossi A, Sandri L, Giangaspero A. Amphipathic, α-helical antimicrobial peptides. Biopolymers. 2000;55(1):4–30. doi:10.1002/1097-0282(2000)55:1<4::AID-BIP30>3.0.CO;2-M10931439
   PubMed Web of Science ®Google Scholar
• Auvynet C, Rosenstein Y. Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS J. 2009;276(22):6497–6508. doi:10.1111/j.1742-4658.2009.07360.x19817855
   PubMed Web of Science ®Google Scholar
• Gallo RL, Murakami M, Ohtake T, Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol. 2002;110(6):823–831.12464945
   PubMed Web of Science ®Google Scholar
• Bals R, Wilson JM. Cathelicidins – a family of multifunctional antimicrobial peptides. Cell Mol Life Sci CMLS. 2003;60(4):711–720.12785718
   PubMed Web of Science ®Google Scholar
• Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 1995;374(1):1–5. doi:10.1016/0014-5793(95)01050-O7589491
   PubMed Web of Science ®Google Scholar
• Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol. 2005;7(2):179–196.16053249
   PubMed Web of Science ®Google Scholar
• Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389–395. doi:10.1038/415389a11807545
   PubMed Web of Science ®Google Scholar
• Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem. 1996;238(2):325–332.8681941
   PubMedGoogle Scholar
• Smeianov V, Scott K, Reid G. Activity of cecropin P1 and FA-LL-37 against urogenital microflora. Microbes Infect. 2000;2(7):773–777. doi:10.1016/S1286-4579(00)90359-910955957
   PubMed Web of Science ®Google Scholar
• Dorschner RA, Pestonjamasp VK, Tamakuwala S, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol. 2001;117(1):91–97. doi:10.1046/j.1523-1747.2001.01340.x11442754
   PubMed Web of Science ®Google Scholar
• Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, Zanetti M. Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J Biol Chem. 1996;271(45):28375–28381.8910461
   PubMed Web of Science ®Google Scholar
• Risso A, Zanetti M, Gennaro R. Cytotoxicity and apoptosis mediated by two peptides of innate immunity. Cell Immunol. 1998;189(2):107–115. doi:10.1006/cimm.1998.13589790724
   PubMed Web of Science ®Google Scholar
• Guermeur Y. Combinaison de Classifieurs Statistiques, Application a La Prediction de La Structure Secondaire Des Proteines [ PhD thesis]. Paris 6; 1997.
   Google Scholar
• Gasteiger E, Hoogland C, Gattiker A, et al. Protein identification and analysis tools on the ExPASy server In: Walker JM, editor. The Proteomics Protocols Handbook. Totowa, NJ: Humana Press; 2005:571–607. Available from: http://link.springer.com/10.1385/1-59259-890-0:571. Accessed 92, 2018.
   Google Scholar
• Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 2016;44(D1):D1087–D1093. doi:10.1093/nar/gkv127826602694
   PubMed Web of Science ®Google Scholar
• Meier A,  Söding J. Automatic Prediction of Protein 3D Structures by Probabilistic Multi-template Homology Modeling. PLOS Computational Biology: Methods 2015:1004343. Available from: https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004343. Accessed 9 3, 2018.
   Google Scholar
• Webb B, Sali A. Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci. 2016;86(1):2.9.1–2.9.37.
   Google Scholar
• Zimmermann L, Stephens A, Nam S-Z, et al. A completely reimplemented MPI bioinformatics toolkit with a new HHpred server at its core. J Mol Biol. 2018;430(15):2237–2243. doi:10.1016/j.jmb.2017.12.00729258817
   PubMed Web of Science ®Google Scholar
• Lovell SC, Davis IW, Arendall III WB, et al. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins Struct Funct Genet. 2003;50:437–450. doi:10.1002/prot.1028612557186
   PubMed Web of Science ®Google Scholar
• Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(suppl_2):W407–W410. doi:10.1093/nar/gkm29017517781
   PubMed Web of Science ®Google Scholar
• Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008;9(1):40. doi:10.1186/1471-2105-9-4018215316
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute, editor. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: M07-A10; Approved Standard. 10th ed. Wayne, PA: Committee for Clinical Laboratory Standards; 2015.
   Google Scholar
• Falciani C, Lozzi L, Pollini S, et al. isomerization of an antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens. plos one. 2012;7(10):e46259. doi:10.1371/journal.pone.004625923056272
   PubMed Web of Science ®Google Scholar
• Luca V, Stringaro A, Colone M, Pini A, Mangoni ML. Esculentin(1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa. Cell Mol Life Sci. 2013;70(15):2773–2786. doi:10.1007/s00018-013-1291-723503622
   PubMed Web of Science ®Google Scholar
• Feng X, Sambanthamoorthy K, Palys T, Paranavitana C. The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. Peptides. 2013;49:131–137. doi:10.1016/j.peptides.2013.09.00724071034
   PubMed Web of Science ®Google Scholar
• Almaaytah A, Tarazi S, Alsheyab F, Al-Balas Q, Mukattash T. Antimicrobial and antibiofilm activity of mauriporin, a multifunctional scorpion venom peptide. Int J Pept Res Ther. 2014;20(4):397–408. doi:10.1007/s10989-014-9405-0
   Web of Science ®Google Scholar
• Parker AE, Walker DK, Goeres DM, Allan N, Olson ME, Omar A. Ruggedness and reproducibility of the MBEC biofilm disinfectant efficacy test. J Microbiol Methods. 2014;102:55–64. doi:10.1016/j.mimet.2014.04.01324815513
   PubMed Web of Science ®Google Scholar
• Hsieh MH, Yu CM, Yu VL, Chow JW. Synergy assessed by checkerboard a critical analysis. Diagn Microbiol Infect Dis. 1993;16(4):343–349. doi:10.1016/0732-8893(93)90087-N8495592
   PubMed Web of Science ®Google Scholar
• Dundar D, Otkun M. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant pseudomonas aeruginosa strains. Yonsei Med J. 2010;51(1):111. doi:10.3349/ymj.2010.51.1.11120046523
   PubMed Web of Science ®Google Scholar
• Angamuthu K, Piramanayagam S. Evaluation of in silico protein secondary structure prediction methods by employing statistical techniques. Biomed Biotechnol Res J BBRJ. 2017;1(1):29. doi:10.4103/bbrj.bbrj_28_17
   Google Scholar
• Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982;157(1):105–132.7108955
   PubMed Web of Science ®Google Scholar
• Schrodinger. The PyMOL Molecular Graphics System, Version 2.0. LLC.
   Google Scholar
• European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect. 2000;6(9):503–508.11168186
   PubMed Web of Science ®Google Scholar
• Oyston PCF, Fox MA, Richards SJ, Clark GC. Novel peptide therapeutics for treatment of infections. J Med Microbiol. 2009;58(Pt 8):977–987. doi:10.1099/jmm.0.011122-019528155
   PubMed Web of Science ®Google Scholar
• Jenssen H, Hamill P, Hancock REW. Peptide antimicrobial agents. Clin Microbiol Rev. 2006;19(3):491–511. doi:10.1128/CMR.00056-0516847082
   PubMed Web of Science ®Google Scholar
• Bahar AA, Ren D. Antimicrobial peptides. Pharmaceuticals. 2013;6(12):1543–1575. doi:10.3390/ph612154324287494
   PubMedGoogle Scholar
• Fjell CD, Hiss JA, Hancock REW, Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov. 2012;11(1):37–51. doi:10.1038/nrd3591
   Web of Science ®Google Scholar
• Hancock REW, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551–1557. doi:10.1038/nbt126717160061
   PubMed Web of Science ®Google Scholar
• Sahl H-G, Pag U, Bonness S, Wagner S, Antcheva N, Tossi A. Mammalian defensins: structures and mechanism of antibiotic activity. J Leukoc Biol. 2005;77(4):466–475. doi:10.1189/jlb.080445215582982
   PubMed Web of Science ®Google Scholar
• Rishi P, Vij S, Maurya IK, Kaur UJ, Bharati S, Tewari R. Peptides as adjuvants for ampicillin and oxacillin against methicillin-resistant Staphylococcus aureus (MRSA). Microb Pathog. 2018;124:11–20. doi:10.1016/j.micpath.2018.08.02330118800
   PubMed Web of Science ®Google Scholar
• Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238–250. doi:10.1038/nrmicro109815703760
   PubMed Web of Science ®Google Scholar
• Hsu C-H, Chen C, Jou M-L, et al. Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Res. 2005;33(13):4053–4064. doi:10.1093/nar/gki72516034027
   PubMed Web of Science ®Google Scholar
• Marchand C, Krajewski K, Lee H-F, et al. Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites. Nucleic Acids Res. 2006;34(18):5157–5165. doi:10.1093/nar/gkl66716998183
   PubMed Web of Science ®Google Scholar
• Cassone M, Otvos JL. Synergy among antibacterial peptides and between peptides and small-molecule antibiotics. Expert Rev Anti Infect Ther. 2010;8(6):703–716. doi:10.1586/eri.10.3820521897
   PubMed Web of Science ®Google Scholar
• Reffuveille F, de la Fuente-Núñez C, Mansour S, Hancock REW. A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob Agents Chemother. 2014;58(9):5363–5371. doi:10.1128/AAC.03163-1424982074
   PubMed Web of Science ®Google Scholar
• Simonetti O, Cirioni O, Ghiselli R, et al. In vitro activity and in vivo animal model efficacy of IB-367 alone and in combination with imipenem and colistin against Gram-negative bacteria. Peptides. 2014;55:17–22. doi:10.1016/j.peptides.2014.01.02924531033
   PubMed Web of Science ®Google Scholar
• Ribeiro SM, de la Fuente-Núñez C, Baquir B, Faria-Junior C, Franco OL, Hancock REW. Antibiofilm peptides increase the susceptibility of carbapenemase-producing klebsiella pneumoniae clinical isolates to β-Lactam antibiotics. Antimicrob Agents Chemother. 2015;59(7):3906–3912. doi:10.1128/AAC.00092-1525896694
   PubMed Web of Science ®Google Scholar
• de la Fuente-Núñez C, Cardoso MH, de Souza Cândido E, Franco OL, Hancock REW. Synthetic antibiofilm peptides. Biochim Biophys Acta BBA – Biomembr. 2016;1858(5):1061–1069. doi:10.1016/j.bbamem.2015.12.015
   Web of Science ®Google Scholar
• Lázár V, Martins A, Spohn R, et al. Antibiotic-resistant bacteria show widespread collateral sensitivity to antimicrobial peptides. Nat Microbiol. 2018;3(6):718–731. doi:10.1038/s41564-018-0164-029795541
   PubMed Web of Science ®Google Scholar
• Rao X-J, Yu X-Q. Lipoteichoic acid and lipopolysaccharide can activate antimicrobial peptide expression in the tobacco hornworm manduca sexta. Dev Comp Immunol. 2010;34(10):1119–1128. doi:10.1016/j.dci.2010.06.00720600279
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Abdelkhalek A, Seleem MN. Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureus. Sci Rep. 2016;6:29707. doi:10.1038/srep29707.
   Web of Science ®Google Scholar
• Ouhara K, Komatsuzawa H, Kawai T, et al. Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus. J Antimicrob Chemother. 2008;61(6):1266–1269. doi:10.1093/jac/dkn10618367458
   PubMed Web of Science ®Google Scholar
• Pompilio A, Crocetta V, Scocchi M, et al. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol. 2012;12(1):145. doi:10.1186/1471-2180-12-14522823964
   PubMed Web of Science ®Google Scholar
• Dastranj M, Farahani A, Shoja S, Dinarvand G. State of globe: biofilm formation in Staphylococcus aureus isolates. J Glob Infect Dis. 2017;9(3):91–92. doi:10.4103/jgid.jgid_83_1728878519
   PubMedGoogle Scholar
• Murray J, Muruko T, Gill CIR, et al. Evaluation of bactericidal and anti-biofilm properties of a novel surface-active organosilane biocide against healthcare associated pathogens and Pseudomonas aeruginosa biolfilm. PLoS One. 2017;12(8):e0182624. doi:10.1371/journal.pone.018262428787014
   PubMed Web of Science ®Google Scholar
• Lee EK, Kim Y-C, Nan YH, Shin SY. Cell selectivity, mechanism of action and LPS-neutralizing activity of bovine myeloid antimicrobial peptide-18 (BMAP-18) and its analogs. Peptides. 2011;32(6):1123–1130. doi:10.1016/j.peptides.2011.03.02421497177
   PubMed Web of Science ®Google Scholar
• Belanger CR, Mansour SC, Pletzer D, Hancock REW. Alternative strategies for the study and treatment of clinical bacterial biofilms. Emerg Top Life Sci. 2017;1(1):41–53. doi:10.1042/ETLS20160020
   Google Scholar
• Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000;31(Supplement_2):S24–S28. doi:10.1086/31405610984324
   PubMed Web of Science ®Google Scholar
• Davis JL, Papich MG. Chapter 65 - Antimicrobial Therapy. In: Sellon DC, Long MT, editors. Equine Infectious Diseases. Second Edition. St. Louis: W.B. Saunders; 2014:571–584.e5. doi:10.1016/B978-1-4557-0891-8.00065-8
   Google Scholar
• Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983;5(Suppl 3):S407–S411.6356275
   PubMedGoogle Scholar
• Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8(6):423–435. doi:10.1038/nrmicro233320440275
   PubMed Web of Science ®Google Scholar
• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev MMBR. 2010;74(3):417–433. doi:10.1128/MMBR.00016-1020805405
   PubMed Web of Science ®Google Scholar